GenScript is a global biotechnology company providing life sciences research and application products and services, with a presence in the USA, Asia-Pacific, and Europe.
GenScript applies its proprietary oligonucleotide and gene synthesis technology to various fields from basic life sciences research to translational biomedical development, industrial synthetic products, and cell therapeutic solutions.
The ERS Genomics license will help further strengthen the GenScript CRISPR portfolio, from providing synthetic sgRNAs, gRNA plasmids, gRNA libraries, to cell line engineering services.
ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.
Financial details of the agreement are not disclosed.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients